Efficacy and safety of rituximab biosimilar in refractory lupus
Open Access
- 2 November 2020
- journal article
- research article
- Published by BMJ in Lupus Science & Medicine
- Vol. 7 (1) , e000442
Abstract
Aims To characterise patients with refractory SLE receiving rituximab biosimilar (CT-P10) and to explore short-term efficacy and safety associated with rituximab biosimilar use. Methods We retrospectively analysed data from the medical records of patients with refractory SLE who received CT-P10 in Ramathibodi Hospital, Mahidol University, Thailand. Baseline characteristics, disease activity (modified Systemic Lupus Erythematosus Disease Activity Index (SLEDAI)), response to treatment at 6 months after CT-P10 and infection over 6 months were recorded. Results Thirty-two patients with SLE received CT-P10 from April 2018 to June 2019. Of these, 29 (90.6%) were female and the mean±SD age was 36.8±15.2 years. The median (IQR) disease duration was 9.5 (1.3–13.0) years. All patients received glucocorticoid treatment and used 1.7±0.1 immunosuppressive agents at baseline, excluding antimalarial drugs. Baseline Systemic Lupus International Collaborating Clinics Damage Index score was 0.5 (0.0–1.0). Overall response, which was defined as a reduction in the modified SLEDAI score of ≥4, was achieved in 25.0% of patients at 6 months. The modified SLEDAI score reduced from 4 (1.3–8.0) at baseline to 1 (0.0–5.8) at 6 months (p=0.005). Response by active organ involvement was 71.8%. Serious infection occurred in four patients (12.5%), resulting in one death. The median time of onset of infection after CT-P10 infusion was 35.5 (17.0–72.5) days. Conclusion Rituximab biosimilar is associated with improvement in active organ involvement in patients with refractory SLE. Infection occurred early after rituximab biosimilar infusion.Keywords
Funding Information
- Faculty of Medicine Ramathibodi Hospital (CF_63001)
This publication has 15 references indexed in Scilit:
- Outcomes of rituximab therapy in refractory lupus: A meta-analysisEuropean Journal of Rheumatology, 2019
- Efficacy and safety of anti-CD20 antibody rituximab for patients with refractory systemic lupus erythematosusLupus, 2018
- B Cell-Based Treatments in SLE: Past Experience and Current DirectionsCurrent Rheumatology Reports, 2017
- Efficacy and safety of off-label use of rituximab in refractory lupus: data from the Italian Multicentre Registry.2015
- Clinical outcomes and safety of rituximab treatment for patients with systemic lupus erythematosus (SLE) – results from a nationwide cohort in Germany (GRAID)Lupus, 2013
- Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: Pooled data from European cohortsAutoimmunity Reviews, 2012
- Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The lupus nephritis assessment with rituximab studyArthritis & Rheumatism, 2012
- Safety and efficacy of rituximab in systemic lupus erythematosus: Results from 136 patients from the French autoimmunity and rituximab registryArthritis & Rheumatism, 2010
- Efficacy and safety of rituximab in moderately‐to‐severely active systemic lupus erythematosus: The randomized, double‐blind, phase ii/iii systemic lupus erythematosus evaluation of rituximab trialArthritis & Rheumatism, 2009
- Rituximab in systemic lupus erythematosusA systematic review of off-label use in 188 casesLupus, 2009